Next Article in Journal
Adenosine Encapsulation and Characterization through Layer-by-Layer Assembly of Hydroxypropyl-β-Cyclodextrin and Whey Protein Isolate as Wall Materials
Next Article in Special Issue
The Molecular Mechanisms of Cuproptosis and Small-Molecule Drug Design in Diabetes Mellitus
Previous Article in Journal
Determination of the Fatty Acid Profile and Lipid Quality Indices in Selected Infant Formulas
Previous Article in Special Issue
Synthesis and Antiproliferative Activity of 2,6-Disubstituted Imidazo[4,5-b]pyridines Prepared by Suzuki Cross Coupling
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Molecules
Volume 29
Issue 9
10.3390/molecules29092048
molecules-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Chemical Constituents and Anticancer Activities of Marine-Derived Fungus Trichoderma lixii

by
Natchanun Sirimangkalakitti
1,
Jianyu Lin
1,
Kazuo Harada
1,
Andi Setiawan
2,
Mitsuhiro Arisawa
1,* and
Masayoshi Arai
1,*
1
Graduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka, Suita 565-0871, Osaka, Japan
2
Department of Chemistry, Faculty of Science, Lampung University, Jl. Prof. Dr. Sumantri Brodjonegoro No. 1, Bandar Lampung 35145, Lampung, Indonesia
*
Authors to whom correspondence should be addressed.
Molecules 2024, 29(9), 2048; https://doi.org/10.3390/molecules29092048
Submission received: 2 March 2024 / Revised: 17 April 2024 / Accepted: 24 April 2024 / Published: 29 April 2024
(This article belongs to the Special Issue Small-Molecule Inhibitors: Synthesis, Cytotoxicity and Biological Activities)
Browse Figure
Review Reports Versions Notes

Abstract

:
The fungal genus Trichoderma is a rich source of structurally diverse secondary metabolites with remarkable pharmaceutical properties. The chemical constituents and anticancer activities of the marine-derived fungus Trichoderma lixii have never been investigated. In this study, a bioactivity-guided investigation led to the isolation of eleven compounds, including trichodermamide A (1), trichodermamide B (2), aspergillazine A (3), DC1149B (4), ergosterol peroxide (5), cerebrosides D/C (6/7), 5-hydroxy-2,3-dimethyl-7-methoxychromone (8), nafuredin A (9), and harzianumols E/F (10/11). Their structures were identified by using various spectroscopic techniques and compared to those in the literature. Notably, compounds 2 and 5–11 were reported for the first time from this species. Evaluation of the anticancer activities of all isolated compounds was carried out. Compounds 2, 4, and 9 were the most active antiproliferative compounds against three cancer cell lines (human myeloma KMS-11, colorectal HT-29, and pancreas PANC-1). Intriguingly, compound 4 exhibited anti-austerity activity with an IC50 of 22.43 μM against PANC-1 cancer cells under glucose starvation conditions, while compound 2 did not.

1. Introduction

Cancer remains a leading cause of mortality worldwide. From the latest global cancer data available in 2021, there were an estimated 19.3 million new cases and 10 million deaths [1], despite continuous efforts to better understand cancer biology and to improve diagnosis and treatment. The ongoing rise in cancer incidence and the limitations, failures, and excessive toxicity of conventional chemotherapies have generated the urgent need for the discovery and development of new anticancer agents [2].
Natural products derived from plants, animals, and microorganisms have a long history of usage in the treatment and prevention of human diseases, especially cancer and infectious diseases [2,3]. Remarkably, over half of all approved anti-cancer drugs between 1981 and 2019 were related to natural sources [4]. Among these, fungi stand as a significant source of secondary metabolites useful for drug discovery [5]. Numerous fungal metabolites and their analogs have advanced to various phases of cancer clinical trials [6].
The fungal genus Trichoderma comprises over 250 species [7] found in most types of soils, decaying wood, and in marine environments from various geographical regions and climatic zones [8,9]. Trichoderma spp. have promising industrial and agricultural potential and are most commonly used as potent biocontrol agents, such as biopesticides, biofertilizers, growth stimulants, and inducers of plant disease resistance [10,11]. In addition to their ecological effects, it is well known that Trichoderma are a prolific source of structurally diverse secondary metabolites, such as terpenes, polyketides, diketopiperazines, peptides, and alkaloids. These chemical entities possess a variety of biological properties, which include antimicrobial, anticancer, antimicroalgal, herbicidal, nematicidal, and enzyme inhibitory properties [8]. The unique structures and modes of action of Trichoderma’s secondary metabolites have inspired a great deal of research interest. It has been suggested that these compounds have the potential for development as new drug candidates [8]. Marine environments, with their extreme conditions and extraordinary ecosystems, have proven to be a treasure trove of biologically active compounds [12]. In the past few decades, the chemistry of marine-derived fungi has received increasing attention. Their potential to produce secondary metabolites that are not found in terrestrial microorganisms has become a subject of intense fascination. Approximately 80 compounds from the marine-derived fungi Trichoderma spp. Have been structurally described, and many of them have shown promising therapeutic properties in drug discovery [13].
Trichoderma lixii, which belongs to the T. harzianum species complex, was named and described in 2015 [14]. Very few studies regarding the chemistry and biological activity of T. lixii have been published so far [15,16,17]. Our interest was stimulated by the observation that solvent extracts exhibited not only significant antiproliferative activity against three cancer cell lines (human myeloma KMS-11, colorectal HT-29, and pancreas PANC-1) but also exhibited anti-austerity activity against PANC-1 cancer cells. This prompted us to investigate the chemical constituents and anticancer activities of T. lixii extract.
In this study, we aim to delve deep into the chemical constituents of T. lixii isolated from marine sponges collected from Mentawai Island, Indonesia, as well as their potential anticancer activities. The scarcity of studies on the chemistry and biological activity of T. lixii underscores the significance of our research.

2. Results and Discussion

2.1. Bioassay-Guided Isolation, Structure Identification and Distribution in Nature

The marine-derived fungus T. lixii was cultivated and then extracted with acetone-based solvents. In a preliminary bioactivity study (Table 1), the acetone extract at 100 μg/mL induced moderate inhibition of cell proliferation among all KMS-11, HT-29, and PANC-1 cell lines (37.9–58.9% inhibition). Notably, it was selectively toxic to PANC-1 cells under glucose starvation conditions (79.51% cytotoxicity) compared to PANC-1 cells under normal glucose conditions (15.32% cytotoxicity). The active acetone extract was then partitioned between ethyl acetate (EtOAc) and water, yielding EtOAc and water-soluble extracts. The EtOAc extract at 100 μg/mL was able to significantly inhibit cell proliferation among all cancer cell lines (71.0–100.5% inhibition) and showed high potency and selectivity to PANC-1 cells under glucose starvation conditions (95.21% cytotoxicity), while the water-soluble extract was inactive. The bioactive EtOAc extract was subjected to n-hexane/methanol (MeOH) partitioning. The n-hexane layer was concentrated to obtain n-hexane extract. The MeOH layer was concentrated and further dissolved in EtOAc to obtain MeOH-1 extract. The residue that did not dissolve in EtOAc was dissolved in MeOH to obtain MeOH-2 extract. The MeOH-1 and MeOH-2 extracts exhibited higher potency in both assays compared to the n-hexane extract.
For reasons of sample quantity, potency, and selectivity (Table 1), we decided to continue the isolation of both bioactive MeOH-1 and MeOH-2 extracts. They were separately subjected to fractionation using various column chromatography techniques. The higher polarity MeOH-2 extract was isolated to obtain three bioactive sub-fractions (A through C). Notably, these sub-fractions showed high potency and selectivity to PANC-1 cells under glucose starvation conditions, particularly sub-fractions A and C. The isolation of sub-fraction A yielded four compounds including trichodermamide A (1), trichodermamide B (2) [18], aspergillazine A (3) [19,20,21], and DC1149B (4) [22]. Ergosterol peroxide (5) [23,24,25] and cerebrosides D/C (6/7) [26] were obtained from the isolation of sub-fractions B and C, respectively.
The lower polarity MeOH-1 extract was fractionated to afford bioactive sub-fraction D. Subsequently, it was further purified to yield 5-hydroxy-2,3-dimethyl-7-methoxychromone (8) [27], nafuredin A (9) [28,29], and harzianumols E/F (10/11) [30]. All isolated compounds were thoroughly characterized using a combination of spectroscopic techniques, including nuclear magnetic resonance (NMR) spectroscopy, high-resolution mass spectrometry (HR-MS), ultraviolet (UV) spectroscopy, and optical rotation measurements. Obtained spectroscopic data (Supplementary Materials) were compared with data from the literature to confirm the structural assignments. Compounds 1–3, 4, 5–7, and 8–11 were classified into modified dipeptides, epidithiodiketopiperazines, lipids and sterols, and polyketides, respectively (Figure 1). In the previous report, compounds 1, 3, and 4 were isolated from this fungal strain [16], while the isolation of the other compounds (2 and 5–11) was the first study of secondary metabolites of T. lixii.
Compound 1 has been found in several species of Trichoderma [16,18,31,32,33,34,35,36] and other genera of fungi [19,20,37,38]. The production of compound 2 correlated with NaCl in a seawater-based medium [18,19,33,39]. It is indicated that Trichoderma spp. are a valuable resource to explore trichodermamides. Compound 3, possessing a sulfide linkage, has been discovered co-existing with compound 1 [16,19,20,34,39]. Compound 4 is a rare type of epithiodiketopiperazine, since the sulfide linkage connects the α- and β-positions of two amino acid residues. The Cl atom in the structure of compound 4 was incorporated from NaCl in a seawater-based medium [33]. To the best of our knowledge, compound 4 was specifically produced by cf. T. brevicompactum [22,33] and T. lixii [16].
Sterol 5 is a well-known, naturally occurring compound obtained from a variety of plants, marine organisms, and fungi, including some Trichoderma spp. [40,41]. Compounds 6/7 were a mixture of cerebrosides D (major) and C (minor) which differ from each other by a double bond at C-3′ and C-4′. Cerebrosides are a class of glycosphingolipids composed of a ceramide molecule, which includes a long-chain fatty acid linked to a sphingosine base, and a sugar molecule, typically glucose or galactose. The chemical structures of 6/7 were conclusively determined based on extensive analyses of NMR, high-resolution matrix-assisted laser desorption/ionization mass spectrometry (HR-MALDI-MS) and fragmentation patterns observed in liquid chromatography–mass spectrometry and tandem mass spectrometry (LC-MS/MS) spectra (Supplementary Materials, Pages 7–8), as well as comparison with the reported data in the literature [26]. Cerebrosides can be found in diverse marine organisms and microorganisms [42]. Previously, 6/7 were isolated from Trichoderma spp. [43,44].
Chromone 8 was isolated from lichen mycobionts and fungi, including some Trichoderma spp. [45,46,47]. Omura and coworkers first reported compound 9 from the sponge-derived fungus Aspergillus niger in 2001 [28]. It is a specific NADH-fumarate reductase inhibitor, which is potentially a selective anthelmintic agent [48]. As its useful biological activity, a total synthesis of compound 9 has been established [49], and later its analogs were developed [50,51,52]. Compound 9 has been obtained from a variety of fungi, not only Aspergillus spp. [28,53] but also Trichoderma spp. [29,45,54,55]. Compounds 10/11 were enantiomers that could not be distinguished with NMR spectra but displayed a pair of peaks in chiral reversed-phase high-pressure liquid chromatography (RP-HPLC). Due to limitations in available resources, the purification of compounds 6/7 and 10/11 was halted and they were reported as a mixture. Compounds 10/11 are C13-polyketides first isolated from the sponge-derived fungus T. harzianum. The C13-polyketide metabolites are rarely found in natural sources and are a group of largely uninvestigated compounds embedded in fungi [30].

2.2. Antiproliferative Activity of Isolated Compounds against Three Cancer Cell Lines (KMS-11, HT-29, and PANC-1) and Human Umbilical Vein Endothelial Cells (HUVEC)

The assessment of antiproliferative effects is a fundamental in vitro assay in the early stages of drug discovery for the screening of potential anticancer compounds that merit further investigation and development for their therapeutic potential in the fight against cancer. The antiproliferative activity of all isolated compounds against three cancer cell lines (KMS-11, HT-29, and PANC-1) was examined by WST-8 based assay according to the manufacturer’s instructions.
As shown in Table 2, after incubation for 48 h, compounds 2, 4, and 9 showed strong antiproliferative activity toward all tested cancer cell lines. In particular, compound 2 showed promising activity, with IC50 values ranging from 0.7 to 3.6 μM against all cancer cells. These values are lower than those reported for cisplatin used as a positive control. Compound 2 is structurally closely related to compound 1, which was completely inactive in all tested cell lines, indicating that the chlorine atom at C-5 is a crucial part of the pharmacophore. The chlorohydrin moiety at C-4 and C-5 may serve as a precursor to an epoxide, which could be the biologically active form of this molecule [18].
Notably, compound 5 has been studied for its potential anticancer properties, which might be attributed to multiple mechanisms such as apoptosis induction, arresting cell cycles, and suppressing cell migration [56,57]; however, different cancer cell lines behaved differently in response to compound 5 in our study (IC50 > 100 μM). A substantial number of cerebrosides have been reported in the literature so far [42]; however, a very small number have undergone more in-depth investigation for their potential against challenging diseases. It is interesting that compounds 6/7 selectively inhibited cell proliferation toward KMS-11 (IC50 21.05 μg/mL).
Compound 8 showed weak or no antimicrobial and 2,2-diphenyl-1-picrylhydrazyl (DPPH) scavenging activities [46,58]. In this study, it showed no antiproliferative activity against all tested cancer cell lines (IC50 > 100 μM) as well. Compound 9 is known as an anthelmintic compound showing selective inhibition of complex I in helminth mitochondria [48]. In addition to anthelmintic activity, compound 9 exhibited antibacterial activity against Escherichia coli, as well as other antimicrobial properties which address ecological and environmental concerns [45,54,55,59]. Surprisingly, in previous studies compound 9 showed no cytotoxicity against several cancer cell lines, including mouse lymphoma L5178Y cell line at 28 μM [29], human cervical HeLa, colon HCT-116, breast MCF-7, lung A549, and leukemia K562 and HL-60 cancer cell lines at 50 μM [60]. On the other hand, in our study, compound 9 strongly inhibited cell proliferation against KMS-11, HT-29, and PANC-1 cancer cell lines with IC50 values ranging from 6.9 to 15.3 μM. Compound 9 is unstable in air because of the oxygen-labile conjugated diene units [61], causing unwanted chemical changes that may result in the loss of bioactivity. Understanding the oxygen sensitivity of compound 9 is important for improving chemical handling and storage to maintain its integrity and prevent degradation of the compound. In addition, our study is the first to demonstrate that rare C13-polyketides (10/11) inhibited cell proliferation of various cancer types (IC50 16.4–39.3 μg/mL).
The antiproliferative activity of all eleven isolated compounds against normal cell line HUVEC was also examined by WST-8 based assay (Table 2). Regrettably, the assessment of active compounds revealed a significant challenge: while they demonstrated toxicity against cancer cells, they also exhibited undesirable effects on HUVEC. Further extensive structural modifications and in-depth structure–activity relationship studies are required to enhance efficacy and reduce the side effects on normal cells.

2.3. Anti-Austerity Activity of Isolated Compounds against PANC-1 Cancer Cell Line

Cancer cells alter their metabolism to promote growth, survival, proliferation, and long-term maintenance. Numerous microenvironmental factors, especially tumor nutrient levels, affect cancer cell metabolism [62]. Since cells in most solid tumors are subjected to strong microenvironmental stresses, including low nutrient and oxygen availability, such cancer cells must develop mechanisms to overcome these unfavorable growth conditions, and therefore eventually gain highly aggressive characteristics [63]. Pancreatic cancer is one of the most aggressive and highly lethal solid tissue malignancies, with a very low 5-year survival rate [64]. Unlike other types of cancer, pancreatic tumors are extremely hypovascular and have a supply of only a limited amount of essential nutrients and oxygen to sustain aggressive growth. Pancreatic cancer cells can develop tolerance to nutrient starvation and adapt to such microenvironmental niches. Such a mechanism of remarkable tolerance is known as “austerity”. There is evidence that tolerating nutrient insufficiency might be an important determinant of tumor progression [65]. The discovery of anti-austerity small molecules that can selectively target cancer cells in nutrient starvation conditions is a promising strategy for the treatment of pancreatic cancer. Anti-austerity agents are less toxic to nutrient-rich cancer cells and thus are expected to have fewer side effects than conventional anticancer drugs. PANC-1 cancer cells have extreme resistance to glucose starvation [65], making them a suitable model for studying an anti-austerity approach.
To evaluate anti-austerity activity, all isolated compounds (1–11) were tested for their cytotoxic effect against PANC-1 cells that were seeded at a high density under both DMEM no glucose (glucose −) and DMEM high glucose media (glucose +). We have searched for natural compounds that show cytotoxicity under glucose starvation conditions, and that are without cytotoxicity under normal glucose conditions. As shown in Table 3, after incubation for 12 h, compounds 2 and 4 showed higher cytotoxic activity against PANC-1 cells adapted to glucose starvation (IC50 17.76 and 22.43 μM, respectively); however, compound 2 did not display selectivity under glucose starvation conditions, as evidenced by a similar IC50 value in normal glucose conditions. The selective index (SI) indicates the preferential cytotoxicity of a compound under glucose starvation conditions, with higher values representing greater selectivity. Compounds 3 and 9 demonstrated moderate cytotoxicity under glucose starvation conditions (IC50 75.59 and 48.97 μM, respectively) and selectivity (SI ≥ 5 and SI = 2, respectively). On the other hand, compounds 1, 5–8, and 10/11, as well as cisplatin, showed no activity against PANC-1 cells under both glucose starvation and normal glucose conditions (IC50 > 100 μM or μg/mL). These results indicated that compound 4, with an SI of 10, emerged as a promising anti-austerity agent, selectively targeting PANC-1 cells adapted to glucose starvation. Our findings corroborate a previous report that identified compound 4, isolated from T. lixii, as an anti-austerity compound against PANC-1 cells through the inhibition of endoplasmic reticulum (ER) stress signaling and complex II in the mitochondrial electron transport chain [16]. The observed differences in IC50 and SI values between the present study and the prior one [16] may be attributed to variations in the glucose starvation media used for the experiments. Our report supports the idea that T. lixii is a valuable resource for the production of an anti-austerity agent of remarkable potential and significance.

3. Materials and Methods

3.1. Instrumentation and General Experimental Techniques

1H- and 13C-NMR spectra were measured on a Varian Inova 600-II NMR spectrometer (Varian, Inc., CA, USA). Chemical shifts were referenced to the following residue solvent peaks: CDCl3 (δH 7.26/δC 77.1), DMSO-d6 (δH 2.50/δC 39.5), or CD3OD (δH 3.31/δC 49.0). HR-MALDI-MS were recorded on a SpiralTOF™ JEOL JMS-S3000 mass spectrometer (JEOL Ltd., Tokyo, Japan). Optical rotations were measured on a Jasco P-1020 polarimeter (JASCO Corporation, Tokyo, Japan) in CHCl3 or MeOH. Silica gel 60 F254 aluminum sheets (Merck, Germany) were used for thin layer chromatography (TLC), and spots on the TLC plate were detected under UV light (254 nm) and by spraying with p-anisaldehyde reagent. Silica gel 60 N, 40–50 μM (Kanto Chemical Co. Inc., Tokyo, Japan) was used for normal-phase flash column chromatography. Reversed-phase medium-pressure liquid chromatography (RP-MPLC) was conducted using a dual channel automated Smart Flash EPCLC-W-Prep 2XY system with a UV detector (Yamazen Corporation, Osaka, Japan). The medium-pressure ODS (C18) chromatographic column (Yamazen Corporation, universal column size L: 3.0 × 16.5 cm; M: 2.3 × 12.3 cm; S: 1.8 × 11.4 cm, pore size 120 Å, particle size 50 μm) was conditioned by first eluting with 100% MeOH or MeCN, then equilibrating with a suitable initial mobile phase. After dissolving the extract in the initial mobile phase, the solution was loaded in the ODS (C18) inject column (Yamazen Corporation, size M: 2.0 × 7.5 cm; S: 1.5 × 4.4 cm; SS: 1.3 × 3.1 cm) and separated by the gradient elution program. The fractions were collected automatically based on time. The purity of each collected fraction was determined by analytical RP-HPLC. An analytical RP-HPLC system was composed of an LC-20AD pump, a DGU-20A3R degasser, a CTO-20AC column oven, and an SPD-M20A diode array detector (Shimadzu Corporation, Kyoto, Japan). Separations were performed on an XBridge® C18 (4.6 × 150 mm, 130 Å, 3.5 μm) coupled with an XBridge® BEH C18 Vanguard® Cartridge (3.9 × 5 mm, 130 Å, 3.5 μm, Waters Corporation, Milford, MA, USA). The mobile phase was composed of either MeOH or MeCN and H2O degassed by sonication. The flow rate was 0.5 mL/min at 25 °C, and the injections were carried out through a 20 μL-loop. Data analysis was performed by LabSolutions (Shimadzu Corporation).

3.2. Fungus Culture

The marine-derived fungus T. lixii strain 15G49-1 was isolated from an unidentified marine sponge which was collected from Mentawai Island, Indonesia, in 2015. The strain was identified as T. lixii by Techno Suruga Laboratory Co., Ltd. (Shizuoka, Japan) based on morphological characteristics and 5.8S ribosomal DNA sequencing. The T. lixii 15G49-1 was maintained on an MG agar plate [2% extract malt (Nacalai Tesque, Inc., Kyoto, Japan), 2% D-(+)-glucose (Nacalai Tesque, Inc.), 0.1% Bactopeptone (Becton Dickinson and Co., Sparks, MD, USA), 3.8% Marine Art SF-1 (Tomita Pharmaceutical, Tokushima, Japan), and 2% agar powder (Nacalai Tesque, Inc.)]. The fungal mycelium on the MG agar plate (1 cm2) was inoculated into 20 test tubes containing 10 mL each of MG broth (2% extract malt, 2% glucose, 0.1% Bactopeptone, and 3.8% Marine Art SF-1) and incubated at 30 °C with shaking at 180 rpm for 8 days. Each fungal inoculum was poured into a 500 mL Erlenmeyer flask containing 25 g of unpolished rice (Japan) and 50 mL of 3.8% Marine Art SF-1, with the addition of artificial sea salt. After that, they were statically cultivated in the solid rice medium for 14 days at 30 °C.

3.3. Extraction, Isolation and Structure Identification

After culturing under the conditions described above, the fungal extract was obtained by sonication for 30 min using acetone (180 mL each × 2) and mixed acetone: MeOH:EtOAc (4:2:1, 160 mL × 1), followed by combining and evaporating the organic solvents under reduced pressure to obtain a crude acetone extract. The extract was partitioned into a 200 mL EtOAc/200 mL water mixture (four times) to obtain EtOAc and water extracts. The bioactive EtOAc extract (13.7 g) was partitioned into a 200 mL n-hexane/200 mL MeOH mixture (four times) to obtain n-hexane (6.0 g) and MeOH extracts. The MeOH extract was separated into two extracts. One extract dissolved well in EtOAc (MeOH-1 extract, 5.2 g) and another extract did not dissolve in EtOAc but dissolved well in MeOH (MeOH-2 extract, 0.6 g).
Following the guidance of bioassays, the MeOH-2 extract was subjected to an RP-MPLC column eluted with 55% MeCN in H2O, 100% MeCN, and 100% EtOH to obtain three sub-fractions A (118.1 mg), B (41.6 mg), and C (93.3 mg), respectively. The most active sub-fraction A was subjected to RP-MPLC (24–38% MeOH in H2O) and then normal-phase (NP) silica gel (1–2% MeOH in CHCl3) columns to yield compounds 1 (1.0 mg), 2 (3.0 mg), 3 (9.6 mg), and 4 (11.0 mg). Purification of sub-fraction B using RP-MPLC (80–85% MeOH in H2O) followed by NP silica gel (30% EtOAc in n-hexane) columns gave 5 (0.9 mg), while purification of sub-fraction C using two NP silica gel columns (5–10% MeOH in EtOAc and then 8–10% MeOH in CH2Cl2) gave 6/7 (1.3 mg). The MeOH-1 extract was fractioned on an NP silica gel column eluted with 60–80% EtOAc in n-hexane to afford sub-fraction D (222.5 mg). Sub-fraction D was purified by using NP silica gel with 0–1% MeOH in CH2Cl2 and RP-MPLC columns with 40–70% MeOH in H2O to yield 8 (0.8 mg), 9 (5.1 mg), and 10/11 (2.0 mg). All isolated compounds were identified by analyses of NMR, HR-MS, LC-MS/MS, UV, and optical rotation values as well as spectroscopic comparison to data from the literature (Supplementary Materials).

3.4. Anticancer Activities

3.4.1. Cell Lines and Cell Culture

Human myeloma KMS-11, colorectal HT-29, and pancreatic PANC-1 cancer cells were obtained from the Japanese Collection of Research Bioresources (JCRB) Cell Bank (JCRB1179, Osaka, Japan), the American Type Culture Collection (ATCC, HTB-38, Manassas, VA, USA), and the Riken BioResource Research Center (BRC, RCB2095, Ibaraki, Japan), respectively. KMS-11, HT-29, and PANC-1 were cultured in Roswell Park Memorial Institute (RPMI)-1640 medium (Nacalai Tesque, Inc.), McCoy’s 5A medium (Gibco Thermo Fisher Scientific Inc., Waltham, MA, USA), and Dulbecco’s Modified Eagle Medium (DMEM) high glucose (Nacalai Tesque, Inc.), respectively. The culture media contained 10% fetal bovine serum (FBS, Equitech-Bio Inc., Kerrville, TX, USA) and 50 μg/mL kanamycin (Fujifilm Wako Pure Chemical Corporation, Osaka, Japan). To induce cell adaptation to nutrient starvation, PANC-1 was cultured in DMEM no glucose (Nacalai Tesque, Inc.) containing 10% dialyzed FBS (Equitech-Bio Inc.) and 50 μg/mL kanamycin. Human umbilical vein endothelial cells (HUVEC) were obtained from Kurabo Industries Ltd., Osaka, Japan (KE-4109) and cultured in HuMedia-EB2 (Kurabo Industries Ltd.) supplemented with HuMedia-EG (2% FBS, 10 ng/mL human epidermal growth factor, 1.34 μg/mL hydrocortisone, antibacterial agents, 50 μg/mL gentamicin and 50 ng/mL amphotericin B, 5 ng/mL human fibroblast growth factor-B, and 10 μg/mL heparin). Cells were incubated in a humidified incubator at 37 °C in an atmosphere of 5% CO2.

3.4.2. Antiproliferative Assay

The antiproliferative activity against cancer and normal cell lines was investigated by a WST-8 based assay. Each cell line was plated in a 96-well flat bottom plate at a low density of 3000 cells/100 μL/well overnight and then treated with crude extracts (final concentration 100 μg/mL) or serially diluted compounds for 48 h. Compounds to be tested were dissolved in DMSO for stock solution (20 μg/mL) and the final concentration of DMSO was 0.5%. Then, 100 μL of corresponding medium containing 10% WST-8 (Nacalai Tesque, Inc.) was added and incubated for up to 4 h. The absorbance of the formazan products was measured at 450 nm using an iMarkTM microplate reader (Bio-Rad Laboratories, Inc. Hercules, CA, USA). Cell viability was obtained from three independent experiments. %Inhibition ± SE values of crude extracts and IC50 ± SE values of tested compounds were determined using Microsoft Excel 2019 (Microsoft Corporation, Redmond, WA, USA) and GraphPad Prism 9 (GraphPad Software, Boston, MA, USA). Cisplatin (Fujifilm Wako Pure Chemical Corporation) was used as a positive control.

3.4.3. Anti-Austerity Assay

The anti-austerity activity against PANC-1 cell line was investigated by a WST-8 based assay according to the method described above. PANC-1 cells were plated in a 96-well flat bottom plate at a high density of 10,000 cells/100 μL/well in a DMEM high glucose medium overnight. The medium was removed, washed with phosphate-buffered saline (PBS, Nissui Pharmaceutical Co., Ltd., Tokyo, Japan) twice, and then replaced with either DMEM high glucose or DMEM no glucose. After incubation for 12 h, crude extracts (final concentration 100 μg/mL) or serially diluted compounds were added, and the cells were incubated for an additional 12 h. Cell viability was evaluated by incubation with 10% WST-8, and %cytotoxicity ± SE values of crude extracts and IC50 ± SE values of tested compounds were determined by the above method. Selective index (SI) was based on the difference between the IC50 values obtained from the high glucose and no glucose media. Antimycin A was used as a positive control.

4. Conclusions

A marine-derived fungus T. lixii has emerged as a valuable source of diverse chemical structures with significant potential in the field of cancer research. Through bioactivity-guided isolation, eleven compounds were isolated, and their structures were elucidated using a combination of spectroscopic techniques and comparison with data from the literature. Compounds 2 and 5–11 were reported for the first time from this species, adding to the novelty of our findings. We demonstrated that compound 4 triggered not only strong antiproliferative activity in different cancer cells but also cytotoxicity in PANC-1 cells under glucose starvation conditions selectively. Our results suggest that compound 4 might be a highly promising lead candidate for the development of new anticancer agents against various cancers, particularly for targeting pancreatic tumors based on an anti-austerity strategy. Overall, our study highlights the potential of secondary metabolites from T. lixii in cancer treatment and encourages further investigation of T. lixii as a source of bioactive molecules for drug discovery and development.

Supplementary Materials

The following supporting information can be downloaded at https://www.mdpi.com/article/10.3390/molecules29092048/s1. Physical and spectral data of 1–11 with citation.

Author Contributions

Conceptualization, M.A. (Mitsuhiro Arisawa). and M.A. (Masayoshi Arai); sample collection, A.S. and M.A. (Masayoshi Arai); methodology, N.S. and J.L.; data analysis, N.S. and K.H.; writing—original draft preparation, N.S.; writing—review and editing, M.A. (Mitsuhiro Arisawa). and M.A. (Masayoshi Arai). All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by The JSPS KAKENHI, Grant No. JP22K15252 to N.S. The authors express their gratitude for partial support by Research Support Project for Life Science and Drug Discovery (Basis for Supporting Innovative Drug Discovery and Life Science Research (BINDS)) from AMED, Grant No. JP21am0101085 and JP22ama121054 to N.S., M.A. (Mitsuhiro Arisawa) and M.A. (Masayoshi Arai), and JSPS KAKENHI, Grant No. 23H02608 to M.A. (Mitsuhiro Arisawa) and Grant No. 21H02069 to M.A. (Masayoshi Arai), Daiichi Sankyo Foundation for Life Sciences to M.A. (Mitsuhrio Arisawa) and The Nippon Foundation—Osaka University Project for Infectious Disease Prevention to M.A. (Mitsuhrio Arisawa). The authors also wish to thank the Kobayashi Foundation for financial assistance to N.S., M.A. (Mitsuhiro Arisawa) and M.A. (Masayoshi Arai).

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Data are contained within the article and Supplementary Materials.

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. Ferlay, J.; Colombet, M.; Soerjomataram, I.; Parkin, D.M.; Pineros, M.; Znaor, A.; Bray, F. Cancer statistics for the year 2020: An overview. Int. J. Cancer 2021, 149, 778–789. [Google Scholar] [CrossRef] [PubMed]
  2. Choudhari, A.S.; Mandave, P.C.; Deshpande, M.; Ranjekar, P.; Prakash, O. Phytochemicals in cancer treatment: From preclinical studies to clinical practice. Front. Pharmacol. 2020, 10, 1614. [Google Scholar] [CrossRef] [PubMed]
  3. Atanasov, A.G.; Zotchev, S.B.; Dirsch, V.M.; The International Natural Product Sciences Taskforce; Supuran, C.T. Natural products in drug discovery: Advances and opportunities. Nat. Rev. Drug Discov. 2021, 20, 200–216. [Google Scholar] [CrossRef] [PubMed]
  4. Newman, D.J.; Cragg, G.M. Natural products as sources of new drugs over the nearly four decades from 01/1981 to 09/2019. J. Nat. Prod. 2020, 83, 770–803. [Google Scholar] [CrossRef] [PubMed]
  5. Gakuubi, M.M.; Munusamy, M.; Liang, Z.-X.; Ng, S.B. Fungal endophytes: A promising frontier for discovery of novel bioactive compounds. J. Fungi 2021, 7, 786. [Google Scholar] [CrossRef] [PubMed]
  6. Kornienko, A.; Evidente, A.; Vurro, M.; Mathieu, V.; Cimmino, A.; Evidente, M.; van Otterlo, W.A.; Dasari, R.; Lefranc, F.; Kiss, R. Toward a cancer drug of fungal origin. Med. Res. Rev. 2015, 35, 937–967. [Google Scholar] [CrossRef] [PubMed]
  7. Bissett, J.; Gams, W.; Jaklitsch, W.; Samuels, G.J. Accepted Trichoderma names in the year 2015. IMA Fungus 2015, 6, 263–295. [Google Scholar] [CrossRef] [PubMed]
  8. Zhang, J.L.; Tang, W.L.; Huang, Q.R.; Li, Y.Z.; Wei, M.L.; Jiang, L.L.; Liu, C.; Yu, X.; Zhu, H.W.; Chen, G.Z.; et al. Trichoderma: A treasure house of structurally diverse secondary metabolites with medicinal importance. Front. Microbiol. 2021, 12, 723828. [Google Scholar] [CrossRef] [PubMed]
  9. Tang, G.T.; Li, Y.; Zhou, Y.; Zhu, Y.H.; Zheng, X.J.; Chang, X.L.; Zhang, S.R.; Gong, G.S. Diversity of Trichoderma species associated with soil in the Zoige alpine wetland of Southwest China. Sci. Rep. 2022, 12, 21709. [Google Scholar] [CrossRef]
  10. Tyskiewicz, R.; Nowak, A.; Ozimek, E.; Jaroszuk-Scisel, J. Trichoderma: The current status of its application in agriculture for the biocontrol of fungal phytopathogens and stimulation of plant growth. Int. J. Mol. Sci. 2022, 23, 2329. [Google Scholar] [CrossRef]
  11. Guzmán-Guzmán, P.; Kumar, A.; de los Santos-Villalobos, S.; Parra-Cota, F.I.; Orozco-Mosqueda, M.D.; Fadiji, A.E.; Hyder, S.; Babalola, O.O.; Santoyo, G. Trichoderma species: Our best fungal allies in the biocontrol of plant diseases—A review. Plants 2023, 12, 432. [Google Scholar] [CrossRef] [PubMed]
  12. Ambrosino, L.; Tangherlini, M.; Colantuono, C.; Esposito, A.; Sangiovanni, M.; Miralto, M.; Sansone, C.; Chiusano, M.L. Bioinformatics for marine products: An overview of resources, bottlenecks, and perspectives. Mar. Drugs 2019, 17, 576. [Google Scholar] [CrossRef]
  13. Su, D.; Ding, L.; He, S. Marine-derived Trichoderma species as a promising source of bioactive secondary metabolites. Mini Rev. Med. Chem. 2018, 18, 1702–1713. [Google Scholar] [CrossRef] [PubMed]
  14. Chaverri, P.; Branco-Rocha, F.; Jaklitsch, W.; Gazis, R.; Degenkolb, T.; Samuels, G.J. Systematics of the Trichoderma harzianum species complex and the re-identification of commercial biocontrol strains. Mycologia 2015, 107, 558–590. [Google Scholar] [CrossRef] [PubMed]
  15. Katoch, M.; Singh, D.; Kapoor, K.K.; Vishwakarma, R.A. Trichoderma lixii (IIIM-B4), an endophyte of Bacopa monnieri L. producing peptaibols. BMC Microbiol. 2019, 19, 98. [Google Scholar] [CrossRef] [PubMed]
  16. Tang, R.; Kimishima, A.; Ishida, R.; Setiawan, A.; Arai, M. Selective cytotoxicity of epidithiodiketopiperazine DC1149B, produced by marine-derived Trichoderma lixii on the cancer cells adapted to glucose starvation. J. Nat. Med. 2020, 74, 153–158. [Google Scholar] [CrossRef] [PubMed]
  17. Li, C.P.; Shi, Z.Z.; Fang, S.T.; Song, Y.P.; Ji, N.Y. Lipids and terpenoids from the deep-sea fungus Trichoderma lixii R22 and their antagonism against two wheat pathogens. Molecules 2023, 28, 6220. [Google Scholar] [CrossRef] [PubMed]
  18. Garo, E.; Starks, C.M.; Jensen, P.R.; Fenical, W.; Lobkovsky, E.; Clardy, J. Trichodermamides A and B, cytotoxic modified dipeptides from the marine-derived fungus Trichoderma virens. J. Nat. Prod. 2003, 66, 423–426. [Google Scholar] [CrossRef]
  19. Capon, R.J.; Ratnayake, R.; Stewart, M.; Lacey, E.; Tennant, S.; Gill, J.H. Aspergillazines A-E: Novel heterocyclic dipeptides from an Australian strain of Aspergillus unilateralis. Org. Biomol. Chem. 2005, 3, 123–129. [Google Scholar] [CrossRef]
  20. Liu, R.; Gu, Q.Q.; Zhu, W.M.; Cui, C.B.; Fan, G.T. Trichodermamide A and aspergillazine A, two cytotoxic modified dipeptides from a marine-derived fungus Spicaria elegans. Arch. Pharm. Res. 2005, 28, 1042–1046. [Google Scholar] [CrossRef]
  21. Yamazaki, H.; Rotinsulu, H.; Takahashi, O.; Kirikoshi, R.; Namikoshi, M. Induced production of a new dipeptide with a disulfide bridge by long-term fermentation of marine-derived Trichoderma cf. brevicompactum. Tetrahedron Lett. 2016, 57, 5764–5767. [Google Scholar] [CrossRef]
  22. Yamazaki, H.; Takahashi, O.; Murakami, K.; Namikoshi, M. Induced production of a new unprecedented epitrithiodiketopiperazine, chlorotrithiobrevamide, by a culture of the marine-derived Trichoderma cf. brevicompactum with dimethyl sulfoxide. Tetrahedron Lett. 2015, 56, 6262–6265. [Google Scholar] [CrossRef]
  23. Kim, D.S.; Baek, N.I.; Oh, S.R.; Jung, K.Y.; Lee, I.S.; Kim, J.H.; Lee, H.K. Anticomplementary activity of ergosterol peroxide from Naematoloma fasciculare and reassignment of NMR data. Arch. Pharm. Res. 1997, 20, 201–205. [Google Scholar] [CrossRef] [PubMed]
  24. Nam, K.S.; Jo, Y.S.; Kim, Y.H.; Hyun, J.W.; Kim, H.W. Cytotoxic activities of acetoxyscirpenediol and ergosterol peroxide from Paecilomyces tenuipes. Life Sci. 2001, 69, 229–237. [Google Scholar] [CrossRef] [PubMed]
  25. Lee, I.S.; Kim, J.P.; Na, M.K.; Jung, H.J.; Min, B.S.; Bae, K.H. Cytotoxicity of ergosterol derivatives from the fruiting bodies of Hygrophorus russula. Nat. Prod. Sci. 2011, 17, 85–89. [Google Scholar]
  26. Jiang, T.; Li, T.; Li, J.; Fu, H.Z.; Pei, Y.H.; Lin, W.H. Cerebroside analogues from marine-derived fungus Aspergillus flavipes. J. Asian Nat. Prod. Res. 2004, 6, 249–257. [Google Scholar] [CrossRef] [PubMed]
  27. Takenaka, Y.; Tanahashi, T.; Nagakura, N.; Hamada, N. 2, 3-Dialkylchromones from mycobiont cultures of the lichen Graphis scripta. Heterocycles 2000, 53, 1589–1593. [Google Scholar] [CrossRef]
  28. Ui, H.; Shiomi, K.; Yamaguchi, Y.; Masuma, R.; Nagamitsu, T.; Takano, D.; Sunazuka, T.; Namikoshi, M.; Omura, S. Nafuredin, a novel inhibitor of NADH-fumarate reductase, produced by Aspergillus niger FT-0554. J. Antibiot. 2001, 54, 234–238. [Google Scholar] [CrossRef]
  29. Damour, H.; Okoye, F.; Proksch, P.; Hakiki, A.; Mosaddak, M.; Hegazy, M.; Debbab, A. Pretrichodermamide A and nafuredin from Trichoderma sp, an endophyte of Cola nitida. J. Mater. Environ. Sci. 2015, 6, 779–783. [Google Scholar]
  30. Li, B.; Huang, Q.X.; Gao, D.; Liu, D.; Ji, Y.B.; Liu, H.G.; Lin, W.H. New C13 lipids from the marine-derived fungus Trichoderma harzianum. J. Asian Nat. Prod. Res. 2015, 17, 468–474. [Google Scholar] [CrossRef]
  31. Seephonkai, P.; Kongsaeree, P.; Prabpai, S.; Isaka, M.; Thebtaranonth, Y. Transformation of an irregularly bridged epidithiodiketopiperazine to trichodermamide A. Org. Lett. 2006, 8, 3073–3075. [Google Scholar] [CrossRef] [PubMed]
  32. Li, D.L.; Chen, Y.C.; Tao, M.H.; Li, H.H.; Zhang, W.M. Two new octahydronaphthalene derivatives from Trichoderma spirale, an endophytic fungus derived from Aquilaria sinensis. Helv. Chim. Acta 2012, 95, 805–809. [Google Scholar] [CrossRef]
  33. Yamazaki, H.; Rotinsulu, H.; Narita, R.; Takahashi, R.; Namikoshi, M. Induced production of halogenated epidithiodiketopiperazines by a marine-derived Trichoderma cf. brevicompactum with sodium halides. J. Nat. Prod. 2015, 78, 2319–2321. [Google Scholar] [CrossRef] [PubMed]
  34. Sun, J.; Pei, Y.; Li, E.; Li, W.; Hyde, K.D.; Yin, W.B.; Liu, X. A new species of Trichoderma hypoxylon harbours abundant secondary metabolites. Sci. Rep. 2016, 6, 37369. [Google Scholar] [CrossRef] [PubMed]
  35. Yamazaki, H.; Takahashi, O.; Kirikoshi, R.; Yagi, A.; Ogasawara, T.; Bunya, Y.; Rotinsulu, H.; Uchida, R.; Namikoshi, M. Epipolythiodiketopiperazine and trichothecene derivatives from the NaI-containing fermentation of marine-derived Trichoderma cf. brevicompactum. J. Antibiot. 2020, 73, 559–567. [Google Scholar] [CrossRef] [PubMed]
  36. Wang, C.F.; Ma, J.; Jing, Q.Q.; Cao, X.Z.; Chen, L.; Chao, R.; Zheng, J.Y.; Shao, C.L.; He, X.X.; Wei, M.Y. Integrating activity-guided strategy and fingerprint analysis to target potent cytotoxic brefeldin A from a fungal library of the medicinal mangrove Acanthus ilicifolius. Mar. Drugs 2022, 20, 432. [Google Scholar] [CrossRef] [PubMed]
  37. Lan, W.J.; Fu, S.J.; Xu, M.Y.; Liang, W.L.; Lam, C.K.; Zhong, G.H.; Xu, J.; Yang, D.P.; Li, H.J. Five new cytotoxic metabolites from the marine fungus Neosartorya pseudofischeri. Mar. Drugs 2016, 14, 18. [Google Scholar] [CrossRef]
  38. Ghule, M.R.; Sawant, I.S.; Oulkar, D.; Hingmire, S.; Shabeer, A.; Holkar, S. Identification of secondary metabolites in mycoparasites Fusarium strains and antifungal activity of fusaric acid against Plasmopara viticola. Arch. Phytopathol. Plant Prot. 2021, 55, 1283–1297. [Google Scholar] [CrossRef]
  39. Wang, Y.; Lu, Z.; Sun, K.; Zhu, W. Effects of high salt stress on secondary metabolite production in the marine-derived fungus Spicaria elegans. Mar. Drugs 2011, 9, 535–542. [Google Scholar] [CrossRef]
  40. Ma, L.; Liu, W.; Huang, Y.; Rong, X. Two acid sorbicillin analogues from saline lands-derived fungus Trichoderma sp. J. Antibiot. 2011, 64, 645–647. [Google Scholar] [CrossRef]
  41. Kaushik, N.; Diaz, C.E.; Chhipa, H.; Julio, L.F.; Andres, M.F.; Gonzalez-Coloma, A. Chemical composition of an aphid antifeedant extract from an endophytic fungus, Trichoderma sp. EFI671. Microorganisms 2020, 8, 420. [Google Scholar] [CrossRef] [PubMed]
  42. Zahran, E.M.; Sayed, A.M.; Abdelwahab, M.F.; Albohy, A.; Abdulrazik, B.S.; Ibrahim, A.M.; Bringmann, G.; Abdelmohsen, U.R. Identifying the specific-targeted marine cerebrosides against SARS-CoV-2: An integrated computational approach. RSC Adv. 2021, 11, 36042–36059. [Google Scholar] [CrossRef] [PubMed]
  43. Qin, X.Y.; Yang, K.L.; Wang, C.Y.; Shao, C.L. Secondary metabolites of the zoanthid-derived fungus Trichoderma sp. TA26-28 collected from the South China Sea. Chem. Nat. Compd. 2014, 50, 961–964. [Google Scholar] [CrossRef]
  44. Zhang, J.C.; Chen, G.Y.; Li, X.Z.; Hu, M.; Wang, B.Y.; Ruan, B.H.; Zhou, H.; Zhao, L.X.; Zhou, J.; Ding, Z.T.; et al. Phytotoxic, antibacterial, and antioxidant activities of mycotoxins and other metabolites from Trichoderma sp. Nat. Prod. Res. 2017, 31, 2745–2752. [Google Scholar] [CrossRef] [PubMed]
  45. Liang, X.R.; Miao, F.P.; Song, Y.P.; Guo, Z.Y.; Ji, N.Y. Trichocitrin, a new fusicoccane diterpene from the marine brown alga-endophytic fungus Trichoderma citrinoviride cf-27. Nat. Prod. Res. 2016, 30, 1605–1610. [Google Scholar] [CrossRef]
  46. Ding, Z.; Tao, T.; Wang, L.; Zhao, Y.; Huang, H.; Zhang, D.; Liu, M.; Wang, Z.; Han, J. Bioprospecting of novel and bioactive metabolites from endophytic fungi isolated from rubber tree Ficus elastica leaves. J. Microbiol. Biotechnol. 2019, 29, 731–738. [Google Scholar] [CrossRef]
  47. Siebatcheu, E.C.; Wetadieu, D.; Youassi Youassi, O.; Bedine Boat, M.A.; Bedane, K.G.; Tchameni, N.S.; Sameza, M.L. Secondary metabolites from an endophytic fungus Trichoderma erinaceum with antimicrobial activity towards Pythium ultimum. Nat. Prod. Res. 2023, 37, 657–662. [Google Scholar] [CrossRef]
  48. Omura, S.; Miyadera, H.; Ui, H.; Shiomi, K.; Yamaguchi, Y.; Masuma, R.; Nagamitsu, T.; Takano, D.; Sunazuka, T.; Harder, A.; et al. An anthelmintic compound, nafuredin, shows selective inhibition of complex I in helminth mitochondria. Proc. Natl. Acad. Sci. USA 2001, 98, 60–62. [Google Scholar] [CrossRef] [PubMed]
  49. Takano, D.; Nagamitsu, T.; Ui, H.; Shiomi, K.; Yamaguchi, Y.; Masuma, R.; Kuwajima, I.; Ōmura, S. Total synthesis of nafuredin, a selective NADH-fumarate reductase inhibitor. Org. Lett. 2001, 3, 2289–2291. [Google Scholar] [CrossRef]
  50. Nagamitsu, T.; Takano, D.; Shiomi, K.; Ui, H.; Yamaguchi, Y.; Masuma, R.; Harigaya, Y.; Kuwajima, I.; Ōmura, S. Total synthesis of nafuredin-γ, a γ-lactone related to nafuredin with selective inhibitory activity against NADH-fumarate reductase. Tetrahedron Lett. 2003, 44, 6441–6444. [Google Scholar] [CrossRef]
  51. Nagamitsu, T.; Takano, D.; Seki, M.; Arima, S.; Ohtawa, M.; Shiomi, K.; Harigaya, Y.; Ōmura, S. The total synthesis and biological evaluation of nafuredin-γ and its analogues. Tetrahedron 2008, 64, 8117–8127. [Google Scholar] [CrossRef]
  52. Ohtawa, M.; Arima, S.; Shimizu, R.; Hanatani, N.; Shimizu, E.; Shiomi, K.; Kita, K.; Omura, S.; Nagamitsu, T. Development of a new air-stable structure-simplified nafuredin-γ analog as a potent and selective nematode complex I inhibitor. J. Antibiot. 2017, 70, 647–654. [Google Scholar] [CrossRef] [PubMed]
  53. Lamboni, Y.; Nielsen, K.F.; Linnemann, A.R.; Gezgin, Y.; Hell, K.; Nout, M.J.; Smid, E.J.; Tamo, M.; van Boekel, M.A.; Hoof, J.B.; et al. Diversity in secondary metabolites including mycotoxins from strains of Aspergillus Section Nigri isolated from raw cashew nuts from Benin, West Africa. PLoS ONE 2016, 11, e0164310. [Google Scholar] [CrossRef]
  54. Zhao, D.L.; Zhang, X.F.; Huang, R.H.; Wang, D.; Wang, X.Q.; Li, Y.Q.; Zheng, C.J.; Zhang, P.; Zhang, C.S. Antifungal nafuredin and epithiodiketopiperazine derivatives from the mangrove-derived fungus Trichoderma harzianum D13. Front. Microbiol. 2020, 11, 1495. [Google Scholar] [CrossRef] [PubMed]
  55. Yu, J.Y.; Shi, T.; Zhou, Y.; Xu, Y.; Zhao, D.L.; Wang, C.Y. Naphthalene derivatives and halogenate quinoline from the coral-derived fungus Trichoderma harzianum (XS-20090075) through OSMAC approach. J. Asian Nat. Prod. Res. 2021, 23, 250–257. [Google Scholar] [CrossRef] [PubMed]
  56. Yang, Y.; Luo, X.; Yasheng, M.; Zhao, J.; Li, J.; Li, J. Ergosterol peroxide from Pleurotus ferulae inhibits gastrointestinal tumor cell growth through induction of apoptosis via reactive oxygen species and endoplasmic reticulum stress. Food Funct. 2020, 11, 4171–4184. [Google Scholar] [CrossRef] [PubMed]
  57. Lin, Y.; Wen, B.; Zhang, Z.; Cai, J. Ergosterol peroxide: An effect-directed detecting method from Anoectochilus elwesii and evaluation of anticancer activity. Nat. Prod. Res. 2022, 36, 3177–3182. [Google Scholar] [CrossRef] [PubMed]
  58. Song, Q.; Yang, S.Q.; Li, X.M.; Hu, X.Y.; Li, X.; Wang, B.G. Aromatic polyketides from the deep-sea cold-seep mussel associated endozoic fungus Talaromyces minioluteus CS-138. Mar. Drugs 2022, 20, 529. [Google Scholar] [CrossRef] [PubMed]
  59. Wu, Y.M.; Yang, X.Q.; Li, S.Y.; Sun, L.J.; Cen, R.H.; Zhao, L.X.; Yang, Y.B.; Ding, Z.T. Three new azaphilone phytotoxins from coculture of the phytopathogens Nigrospora oryzae and Colletotrichum gloeosporioides and antifungal activities against N. oryzae. Chem. Nat. Compd. 2022, 58, 848–852. [Google Scholar] [CrossRef]
  60. Zhang, Z.; He, X.; Zhang, G.; Che, Q.; Zhu, T.; Gu, Q.; Li, D. Inducing secondary metabolite production by combined culture of Talaromyces aculeatus and Penicillium variabile. J. Nat. Prod. 2017, 80, 3167–3171. [Google Scholar] [CrossRef]
  61. Ohtawa, M.; Matsunaga, M.; Fukunaga, K.; Shimizu, R.; Shimizu, E.; Arima, S.; Ohmori, J.; Kita, K.; Shiomi, K.; Omura, S.; et al. Design, synthesis, and biological evaluation of air-stable nafuredin-γ analogs as complex I inhibitors. Bioorg. Med. Chem. 2015, 23, 932–943. [Google Scholar] [CrossRef] [PubMed]
  62. Sullivan, M.R.; Danai, L.V.; Lewis, C.A.; Chan, S.H.; Gui, D.Y.; Kunchok, T.; Dennstedt, E.A.; Vander Heiden, M.G.; Muir, A. Quantification of microenvironmental metabolites in murine cancers reveals determinants of tumor nutrient availability. eLife 2019, 8, e44235. [Google Scholar] [CrossRef] [PubMed]
  63. Endo, H.; Owada, S.; Inagaki, Y.; Shida, Y.; Tatemichi, M. Glucose starvation induces LKB1-AMPK-mediated MMP-9 expression in cancer cells. Sci. Rep. 2018, 8, 10122. [Google Scholar] [CrossRef] [PubMed]
  64. Hu, J.X.; Zhao, C.F.; Chen, W.B.; Liu, Q.C.; Li, Q.W.; Lin, Y.Y.; Gao, F. Pancreatic cancer: A review of epidemiology, trend, and risk factors. World J. Gastroenterol. 2021, 27, 4298–4321. [Google Scholar] [CrossRef]
  65. Izuishi, K.; Kato, K.; Ogura, T.; Kinoshita, T.; Esumi, H. Remarkable tolerance of tumor cells to nutrient deprivation: Possible new biochemical target for cancer therapy. Cancer Res. 2000, 60, 6201–6207. [Google Scholar]
Molecules 29 02048 g001
Figure 1. Eleven compounds isolated from the marine-derived fungus Trichoderma lixii.
Figure 1. Eleven compounds isolated from the marine-derived fungus Trichoderma lixii.
Molecules 29 02048 g001
Table 1. Anticancer activities of crude extracts and sub-fractions at 100 μg/mL.
Table 1. Anticancer activities of crude extracts and sub-fractions at 100 μg/mL.
Crude ExtractsAntiproliferative Activity
(% Inhibition ± SE)		Anti-Austerity Activity
(% Cytotoxicity ± SE)
KMS-11HT-29PANC-1PANC-1
Glucose −Glucose +Selectivity
acetone58.88 ± 4.37 53.11 ± 2.96 37.91 ± 4.0779.51 ± 5.7315.32 ± 0.68selective
EtOAc100.47 ± 1.0090.44 ± 4.4371.02 ± 4.78 95.21 ± 1.2140.57 ± 6.16selective
water5.83 ± 5.85 3.96 ± 6.6412.17 ± 5.43−0.50 ± 4.630.92 ± 2.38ND
n-hexane72.42 ± 6.69 23.56 ± 6.0930.44 ± 0.4640.88 ± 4.2022.12 ± 1.87selective
MeOH-199.88 ± 1.3093.48 ± 2.1084.87 ± 2.83100.53 ± 2.8871.14 ± 2.80selective
MeOH-275.93 ± 0.44102.40 ± 1.5999.54 ± 0.4799.09 ± 0.4365.71 ± 4.28selective
sub-fraction ANT100.63 ± 2.0341.26 ± 1.30selective
sub-fraction B62.99 ± 5.553.72 ± 6.38selective
sub-fraction C97.59 ± 2.2126.13 ± 4.10selective
sub-fraction D68.75 ± 2.7237.39 ± 5.66selective
SE: standard error of mean of IC50; KMS-11: human myeloma cell line; HT-29: human colorectal cell line; PANC-1: human pancreas cell line; NT: not tested; Glucose −: under glucose starvation conditions (DMEM no glucose media); Glucose +: under normal glucose conditions (DMEM high glucose media); ND: not determined (no activity under Glucose −; thus, selectivity cannot be determined).
Table 2. Antiproliferative activity of isolated compounds (1–11) against three cancer cell lines (KMS-11, HT-29, and PANC-1) and HUVEC.
Table 2. Antiproliferative activity of isolated compounds (1–11) against three cancer cell lines (KMS-11, HT-29, and PANC-1) and HUVEC.
CompoundsAntiproliferative Activity (IC50 ± SE)
KMS-11HT-29PANC-1HUVEC
1>100μM>100μM>100μM>100μM
21.38 ± 0.12μM0.73 ± 0.12μM3.58 ± 0.32μM1.69 ± 0.26μM
337.97 ± 7.72μM22.20 ± 3.09μM50.29 ± 4.21μM26.20 ± 5.51μM
47.60 ± 0.40μM39.18 ± 4.60μM24.67 ± 4.44μM6.94 ± 0.86μM
5>100μM>100μM>100μM>100μM
6/721.05 ± 3.21μg/mL>100μg/mL>100μg/mL31.27 ± 2.99μg/mL
8>100μM>100μM>100μM>100μM
96.90 ± 1.84μM11.88 ± 0.55μM15.27 ± 0.44μM2.45 ± 0.16μM
10/1116.41 ± 2.23μg/mL32.51 ± 1.68μg/mL39.27 ± 2.57μg/mL15.32 ± 0.64μg/mL
Cisplatin4.91 ± 1.06μM10.59 ± 0.83μM28.62 ± 3.43μM13.72 ± 2.57μM
IC50: 50% inhibitory concentration; SE: standard error of mean of IC50; KMS-11: human myeloma cell line; HT-29: human colorectal cell line; PANC-1: human pancreas cell line; HUVEC: human umbilical vein endothelial cells.
Table 3. Anti-austerity activity of isolated compounds (1–11) against PANC-1 cancer cells.
Table 3. Anti-austerity activity of isolated compounds (1–11) against PANC-1 cancer cells.
CompoundsAnti-Austerity Activity (IC50 ± SE)
Glucose −Glucose +Selectivity
1>100μM>100μMND
217.76 ± 4.75μM11.58 ± 1.59μMnot selective
375.59 ± 4.08μM>400μMselective (SI ≥ 5)
422.43 ± 2.50μM213.37 ± 4.07μMselective (SI = 10)
5>100μM>100μMND
6/7>100μg/mL>100μg/mLND
8>100μM>100μMND
948.97 ± 1.31μM76.66 ± 3.22μMselective (SI = 2)
10/11>100μg/mL>100μg/mLND
Antimycin A16.23 ± 0.26nM>300μMselective (SI ≥ 18,480)
Cisplatin>100μM>100μMND
IC50: 50% inhibitory concentration; SE: standard error of mean of IC50; Glucose −: under glucose starvation conditions (DMEM no glucose media); Glucose +: under normal glucose conditions (DMEM high glucose media); SI: selective index; ND: not determined (no activity under Glucose −, thus, selectivity cannot be determined).
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Sirimangkalakitti, N.; Lin, J.; Harada, K.; Setiawan, A.; Arisawa, M.; Arai, M. Chemical Constituents and Anticancer Activities of Marine-Derived Fungus Trichoderma lixii. Molecules 2024, 29, 2048. https://doi.org/10.3390/molecules29092048

AMA Style

Sirimangkalakitti N, Lin J, Harada K, Setiawan A, Arisawa M, Arai M. Chemical Constituents and Anticancer Activities of Marine-Derived Fungus Trichoderma lixii. Molecules. 2024; 29(9):2048. https://doi.org/10.3390/molecules29092048

Chicago/Turabian Style

Sirimangkalakitti, Natchanun, Jianyu Lin, Kazuo Harada, Andi Setiawan, Mitsuhiro Arisawa, and Masayoshi Arai. 2024. "Chemical Constituents and Anticancer Activities of Marine-Derived Fungus Trichoderma lixii" Molecules 29, no. 9: 2048. https://doi.org/10.3390/molecules29092048

APA Style

Sirimangkalakitti, N., Lin, J., Harada, K., Setiawan, A., Arisawa, M., & Arai, M. (2024). Chemical Constituents and Anticancer Activities of Marine-Derived Fungus Trichoderma lixii. Molecules, 29(9), 2048. https://doi.org/10.3390/molecules29092048

Article Metrics

Back to TopTop